| 王 雨,徐裕金.基于新抗原免疫疗效预测研究进展[J].肿瘤学杂志,2023,29(5):367-372. |
| 基于新抗原免疫疗效预测研究进展 |
| Advances on Prediction of Immunotherapy Efficacy Based on Neoantigen |
| 投稿时间：2023-01-20 |
| DOI：10.11735/j.issn.1671-170X.2023.05.B004 |
|
 |
| 中文关键词: 免疫疗法 新抗原 生物标志物 预测 |
| 英文关键词:immunotherapy neoantigen biomarkers prediction |
| 基金项目:浙江省基础公益研究项目（LGF21H160005）；浙江省医药卫生一般项目（2022KY106） |
|
| 摘要点击次数: 487 |
| 全文下载次数: 78 |
| 中文摘要: |
| 摘 要：近年来，新抗原被认为是人体免疫系统识别和触发有效抗肿瘤免疫应答的关键分子，具有高度的免疫原性。研究显示免疫检查点抑制剂的疗效与新抗原的数量相关。因此，新抗原相关的生物标志物可能预测免疫治疗的疗效。全文主要讨论程序性死亡配体1、肿瘤突变负荷、肿瘤新抗原负荷、循环肿瘤DNA和微卫星不稳定性等对免疫治疗的预测价值，新抗原的鉴定方法，以及基于新抗原免疫疗法的应用成果。但实施检测和治疗的过程中也会遇到一些阻碍，例如：检测生物标志物过程繁琐，新抗原疫苗的制作费用高昂等。未来研究者们还需不断探索，找到更有效的生物标志物，使更多的患者从中受益，实现个体化的精准治疗。 |
| 英文摘要: |
| Abstract： Neoantigens have been recognized as key molecules with high immunogenicity for the human immune system to recognize and trigger effective anti-tumor immune responses. Studies have shown that the amount of neoantigen is correlated with the efficacy of immune checkpoint inhibitor therapy， indicating that biomarkers related to neoantigen may be used to predict the efficacy of immunotherapy. This review mainly discusses the predictive value of programmed cell death-ligand 1， tumor mutational burden， tumor neoantigen burden， circulating tumor DNA， and microsatellite instability for immunotherapy， the identification methods of neoantigens， and the results of applying neoantigen-based immunotherapy. However， there are still some obstacles in tests and treatment related to neoantigens， such as the cumbersome process of detecting biomarkers and the high cost of making neoantigen vaccines. It is necessary to explore and find more effective biomarkers of neoantigen in the future to develop personalized and precise treatment for cancer patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |